University of California San Francisco
Give to UCSF
A new study shows how minority patients are effectively disqualified from receiving the latest cystic fibrosis drugs approved only for people with mutations more common among white patients.
We posed the most common COVID-19 vaccine quandaries to Bryn Boslett, MD, an infectious disease expert who is leading the vaccination effort at UCSF. She explains why mRNA vaccines won’t affect your DNA, which allergies pose a risk, what 95 percent efficacy really means, and more.
“It’s too soon to know if this variant will spread more rapidly than others," said Erica Pan, MD, MPH, State Epidemiologist for the California Department of Public Health.
A mutated version of the novel coronavirus has been making the news for being more contagious. We asked UCSF infectious disease expert Charles Chiu, MD, PhD, how the new variant emerged, whether available vaccines will still work, and what we need to do now.
UCSF and BridgeBio Pharma, Inc. today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.
Patterns of brain activity can be used to forecast seizure risk in epilepsy patients several days in advance, according to a new analysis of data obtained from clinically approved brain implants by neuroscientists at UCSF, the University of Bern and the University of Geneva.
The device, which may be a better illness indicator than a thermometer, could lead to earlier isolation and testing, curbing the spread of infectious diseases.
A group at Gladstone Institutes and UCSF has demonstrated that a large-scale and systematic genetic approach can indeed yield reliable and detailed information on the structure of protein complexes.
This type of test could be used as a check against possible errors generated by the standard tests that directly detect the SARS-CoV-2 virus, the scientists said.
Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research.
A new, $9 million grant from the National Cancer Institute to increase ethnic diversity will help the study work toward a goal of enrolling 100,000 or more women overall.
UCSF scientists have developed a single clinical laboratory test capable of zeroing in on the microbial miscreant afflicting a patient in as little as six hours.
Lisa had a rare mutation that meant she was not able to combine two words until she was 3, and she didn’t take part in imaginative play until she was 10. Could a drug for MS be repurposed to help her?
